Intestinal absorption of cadmium is associated with divalent metal transporter 1 in rats.
The intestinal absorption of cadmium (Cd) increases when the body iron (Fe) stores are depleted. The depletion of Fe upregulates the expression of divalent metal transporter 1 (DMT1), which is located at the apical membrane of enterocytes lining the small intestine. DMT1 has been shown to transport Fe and other divalent metal ions in vitro. However, it is not known whether DMT1 mediates the intestinal absorption of Cd. To investigate DMT1 involvement in Cd absorption, rats were fed a diet for 4 weeks either deficient in Fe (FeD diet, 2-6 mg Fe/kg) or supplemented with Fe (FeS diet, 120 mg Fe/kg), followed by a single oral administration of 109 CdCl2. Body Fe status, hemoglobin, and tissue Cd concentration were determined at 48 h after Cd administration. Also, DMT1 mRNA levels were quantified in duodenum, kidney, and liver by the branched DNA signal amplification method. Animals fed the FeD diet exhibited a reduced body weight gain, depletion of body Fe, and Fe deficiency anemia. Tissue Cd concentration was significantly higher in FeD than in FeS diet-fed rats, especially in the duodenum. The amount of Cd retained in the body was 10-fold higher in rats fed the FeD diet than in those fed the FeS diet. DMT1 mRNA was highly expressed in duodenum and was 15-fold higher in the FeD diet group. The levels of DMT1 mRNA were significantly lower in kidney and liver than in duodenum, but were 30 and 40% higher, respectively, in rats fed the FeD diet than in rats fed the FeS diet. These findings suggest that functional DMT1 protein is likely upregulated in the small intestine at the mRNA level by body iron depletion and increases Cd uptake from the gastrointestinal tract with subsequent transfer of Cd to the circulation and body tissues. Furthermore, the data from this study may indicate that DMT1 is a nonspecific metal transporter, which can transport not only Fe, but probably the toxic metal as well.
Park
Jung D
JD
Center for Environmental and Occupational Health, Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160-7417, USA.
Cherrington
Nathan J
NJ
Klaassen
Curtis D
CD
D018798:Anemia, Iron-Deficiency / Q000378:metabolism; D000818:Animals; D001822:Body Burden; D001835:Body Weight / Q000187:drug effects; D002104:Cadmium / Q000493:pharmacokinetics*; D027682:Cation Transport Proteins / Q000096:biosynthesis* / Q000235:genetics; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism; D007408:Intestinal Absorption; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D019266:Iron, Dietary; D033862:Iron-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D008297:Male; D015345:Oligonucleotide Probes / Q000737:chemistry; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation; D000099236:Solute Carrier Family 11, Member 2
D002104:Cadmium; D027682:Cation Transport Proteins; D007501:Iron; D019266:Iron, Dietary; D033862:Iron-Binding Proteins; D015345:Oligonucleotide Probes; D012333:RNA, Messenger; D000099236:Solute Carrier Family 11, Member 2